We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Intel Corporation | NASDAQ:INTC | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.31 | -0.90% | 34.15 | 34.15 | 34.16 | 34.45 | 33.835 | 34.36 | 20,605,253 | 20:18:38 |
From Jul 2019 to Jul 2024
By Colin Kellaher
Healx, a U.K.-based startup using artificial intelligence to develop treatments for rare diseases, on Wednesday said it raised $56 million in a Series B financing round at an undisclosed valuation.
Skype founder Niklas Zennstrom's venture-capital firm Atomico led the round, which brought Healx's total funding to $70 million.
New investors Intel Capital, Global Brain and btov Partners also participated, Healx said, as did all of its previous investors, including Balderton Capital, Amadeus Capital Partners and Jonathan Milner.
Healx said it will use the financing to build a clinical-stage portfolio for rare diseases, including treatments for fragile X syndrome, the leading genetic cause of autism.
The company also will use the funds to launch its global "Rare Treatment Accelerator" program, which aims to work with patients groups to discover new treatments and move them toward the clinic within two years.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 16, 2019 13:03 ET (17:03 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Intel Chart |
1 Month Intel Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
